Plant Name: Aloe microstigma
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; OPRK1; OPRD1; OPRM1; | |
| HTR7; DRD1; DRD2; HTR2A; HTR1A; | |
| PDE10A; | |
| PDE3B; PDE3A; | |
| PDE5A; | |
| PDE2A; | |
| KCNH2; | |
| MTOR; PKM; ALOX12; ALOX15; ALDH1A1; SENP6; SENP8; SENP7; | |
| CA2; CA1; CA12; CA9; CA5B; CA3; CA14; CA7; CA5A; CA4; CA6; | |
| ESR2; | |
| CASP3; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| CREBBP; | |
| SLC22A2; | |
| HTT; LMNA; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cysteine protease | CASP3 | Caspase-3 | P42574 | CHEMBL2334 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Enzyme_unclassified | SENP8 | Sentrin-specific protease 8 | Q96LD8 | CHEMBL1741207 |
| Enzyme_unclassified | SENP7 | Sentrin-specific protease 7 | Q9BQF6 | CHEMBL1741213 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 2 | PDE2A | Phosphodiesterase 2A | O00408 | CHEMBL2652 |
| Phosphodiesterase 3 | PDE3B | Phosphodiesterase 3B | Q13370 | CHEMBL290 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| SLC superfamily of solute carriers | SLC22A2 | Solute carrier family 22 member 2 | O15244 | CHEMBL1743122 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.948E-13 | 2.161E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0047555; 3',5'-cyclic-GMP phosphodiesterase activity | 2.281E-10 | 4.516E-07 | PDE10A, PDE2A, PDE3A, PDE3B, PDE5A |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.275E-08 | 1.459E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.275E-08 | 1.459E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006198; cAMP catabolic process | 4.581E-08 | 2.494E-05 | PDE10A, PDE2A, PDE3A, PDE3B |
| MF | GO:0003824; catalytic activity | GO:0004115; 3',5'-cyclic-AMP phosphodiesterase activity | 6.235E-08 | 3.157E-05 | PDE10A, PDE2A, PDE3A, PDE3B |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.347E-08 | 3.414E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.307E-07 | 5.371E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.638E-07 | 6.370E-05 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CREBBP, ESR2, TP53 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 2.191E-07 | 8.087E-05 | DRD1, DRD2, HTR2A, OPRK1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.295E-07 | 8.138E-05 | ALOX12, ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0046069; cGMP catabolic process | 3.659E-07 | 1.170E-04 | PDE10A, PDE2A, PDE5A |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 6.360E-07 | 1.856E-04 | DRD2, OPRK1, OPRM1, PDE10A, SMN1, SMN2 |
| MF | GO:0060089; molecular transducer activity | GO:0004985; opioid receptor activity | 1.021E-06 | 2.778E-04 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 1.588E-06 | 3.929E-04 | DRD2, MTOR, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.981E-06 | 4.486E-04 | ALOX15, CASP3, MTOR, OPRM1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 2.040E-06 | 4.486E-04 | MTOR, OPRD1, OPRK1, OPRM1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.040E-06 | 4.486E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.179E-06 | 4.718E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 2.990E-06 | 6.201E-04 | HTR1A, HTR2A, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.345E-26 | 5.106E-22 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0031635; adenylate cyclase-inhibiting opioid receptor signaling pathway | 7.108E-06 | 1.191E-03 | OPRK1, OPRM1 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 7.108E-06 | 1.191E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 7.108E-06 | 1.191E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004119; cGMP-inhibited cyclic-nucleotide phosphodiesterase activity | 7.108E-06 | 1.191E-03 | PDE3A, PDE3B |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 8.323E-06 | 1.343E-03 | DRD1, DRD2, HIF1A, MTOR |
| BP | GO:0032501; multicellular organismal process | GO:0006939; smooth muscle contraction | 8.323E-06 | 1.343E-03 | DRD1, DRD2, HTR2A, HTR7 |
| MF | GO:0005488; binding | GO:0030553; cGMP binding | 8.184E-06 | 1.343E-03 | PDE10A, PDE2A, PDE5A |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 8.730E-06 | 1.389E-03 | HIF1A, LMNA, MTOR, OPRD1, TP53 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.001E-05 | 1.535E-03 | DRD1, KCNH2, NFKB1, OPRM1, PDE2A, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.366E-05 | 1.940E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.954E-05 | 2.548E-03 | CA2, CA7, DRD1, DRD2, HTR2A, HTT |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.129E-05 | 2.664E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 2.664E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.129E-05 | 2.664E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004118; cGMP-stimulated cyclic-nucleotide phosphodiesterase activity | 2.129E-05 | 2.664E-03 | PDE10A, PDE2A |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.129E-05 | 2.664E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 2.219E-05 | 2.745E-03 | ALOX15, CA2, CASP3, CYP1A2, DRD2, HIF1A, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.365E-05 | 2.877E-03 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.392E-05 | 2.894E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 2.633E-05 | 3.133E-03 | DRD2, HTR1A, HTR2A, MTOR |
| MF | GO:0005488; binding | GO:0042923; neuropeptide binding | 2.733E-05 | 3.217E-03 | OPRD1, OPRK1, OPRM1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.118E-05 | 3.595E-03 | CA2, CA7, DRD1, DRD2, HIF1A, HTT |
| MF | GO:0005488; binding | GO:0030552; cAMP binding | 3.137E-05 | 3.595E-03 | PDE10A, PDE2A, PDE3A |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.137E-05 | 3.595E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 3.579E-05 | 3.936E-03 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 3.579E-05 | 3.936E-03 | HTR1A, HTR2A, HTR7 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.669E-05 | 4.014E-03 | CA2, CA7, DRD1, DRD2, HIF1A, HTR2A, HTT, OPRK1 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.754E-05 | 4.067E-03 | CREBBP, HIF1A, HTT, TP53 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 4.250E-05 | 4.345E-03 | HTR1A, HTR7 |
| BP | GO:0009987; cellular process | GO:0060282; positive regulation of oocyte development | 4.250E-05 | 4.345E-03 | PDE3A, PDE5A |
| BP | GO:0007610; behavior | GO:0042755; eating behavior | 5.748E-05 | 5.638E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 5.748E-05 | 5.638E-03 | DRD2, HTR2A, OPRK1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 5.797E-05 | 5.661E-03 | CA2, DRD1, DRD2, HIF1A, HTR2A, HTT, MTOR, OPRD1, OPRK1, OPRM1, PKM, SMN1, SMN2 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 6.399E-05 | 6.166E-03 | HTR1A, HTR2A, HTR7 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 7.071E-05 | 6.666E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 7.071E-05 | 6.666E-03 | ALOX12, ALOX15 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 7.843E-05 | 7.267E-03 | DRD1, DRD2, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0071321; cellular response to cGMP | 1.059E-04 | 9.373E-03 | PDE2A, PDE3A |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.059E-04 | 9.373E-03 | CA1, CA2 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.106E-04 | 9.747E-03 | CREBBP, DRD2, HTR7, OPRK1, OPRM1, TP53 |
| BP | GO:0008283; cell proliferation | GO:2000648; positive regulation of stem cell proliferation | 1.133E-04 | 9.950E-03 | DRD2, HIF1A, THPO |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.245E-19 | 1.356E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.921E-18 | 1.046E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.445E-25 | 1.979E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.175E-11 | 8.051E-10 | CYP2C9; HTR7; CYP2D6; CASP3; ALOX15; HTR1A; ALOX12; HTR2A; CYP2C19 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.316E-08 | 1.183E-06 | CREBBP; PDE3B; HTR1A; PDE3A; DRD1; DRD2; NFKB1; TSHR |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.599E-08 | 1.183E-06 | OPRD1; HTR7; HTR1A; OPRK1; OPRM1; HTR2A; DRD1; DRD2; TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.105E-08 | 5.045E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.292E-07 | 2.950E-06 | PDE10A; PDE3B; PDE2A; PDE3A; OPRM1; DRD1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.667E-07 | 1.892E-05 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00230 | Purine metabolism_Homo sapiens_hsa00230 | 6.206E-06 | 1.063E-04 | PKM; PDE10A; PDE2A; PDE3B; PDE3A; PDE5A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.027E-05 | 3.086E-04 | CYP2C9; ALOX15; ALOX12; CYP2C19 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.816E-05 | 4.081E-04 | CREBBP; CASP3; STAT6; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.759E-05 | 3.436E-04 | PKM; TP53; HIF1A; MTOR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.446E-05 | 3.351E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.235E-05 | 6.608E-04 | OPRD1; PDE2A; PDE3B; PDE3A; PDE5A |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.873E-05 | 4.081E-04 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.425E-05 | 7.214E-04 | CREBBP; TP53; NFKB1; MTOR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.893E-04 | 1.441E-03 | CREBBP; PKM; CASP3; TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.117E-05 | 5.986E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.485E-04 | 1.197E-03 | CREBBP; HIF1A; NFKB1; MTOR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.546E-04 | 3.454E-03 | CREBBP; CASP3; HIF1A; TP53; NFKB1; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.505E-04 | 1.806E-03 | CREBBP; TP53; HIF1A; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.798E-04 | 3.130E-03 | CASP3; LMNA; TP53; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 7.558E-04 | 4.502E-03 | CREBBP; THPO; STAT6; MTOR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.025E-03 | 5.853E-03 | CREBBP; CASP3; TP53; NFKB1; MTOR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.807E-04 | 1.923E-03 | DRD1; DRD2; NFKB1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.585E-03 | 7.926E-03 | CREBBP; CASP3; HTT; TP53 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.357E-03 | 7.435E-03 | CREBBP; CASP3; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.906E-03 | 8.705E-03 | CASP3; TP53; HIF1A; MTOR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.881E-03 | 8.705E-03 | TP53; NFKB1; MTOR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.557E-03 | 7.926E-03 | HTR2A; DRD1; DRD2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.309E-03 | 9.884E-03 | SLC22A2; HIF1A; MTOR |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.309E-03 | 9.884E-03 | CREBBP; PKM; PDE3B |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.758E-03 | 1.560E-02 | OPRD1; TP53; NFKB1 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 6.006E-03 | 2.420E-02 | CASP3; DRD1; DRD2 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.147E-02 | 3.544E-02 | HTR7; HTR2A; DRD1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.113E-02 | 3.544E-02 | CREBBP; CASP3; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.402E-02 | 3.624E-02 | CYP2C9; PKM; CYP1A2; ALOX15; ALDH1A1; ALOX12; CYP2C19; CYP3A4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.335E-03 | 3.365E-02 | PDE3B; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.561E-02 | 3.687E-02 | CREBBP; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.658E-03 | 3.393E-02 | NFKB1; MTOR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.066E-02 | 3.544E-02 | HIF1A; MTOR |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.016E-03 | 3.339E-02 | CASP3; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.929E-03 | 2.712E-02 | PKM; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.242E-02 | 3.544E-02 | TP53; MTOR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.135E-02 | 3.544E-02 | CASP3; TP53 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 7.793E-03 | 2.966E-02 | CASP3; TP53 |
| hsa04924 | Renin secretion_Homo sapiens_hsa04924 | 1.206E-02 | 3.544E-02 | PDE3B; PDE3A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.279E-02 | 3.544E-02 | TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.279E-02 | 3.544E-02 | CREBBP; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.987E-03 | 3.421E-02 | CYP1A2; CYP3A4 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.242E-02 | 3.544E-02 | STAT6; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.509E-02 | 3.687E-02 | NFKB1; ESR2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.354E-02 | 3.624E-02 | CASP3; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.549E-02 | 3.687E-02 | TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.109E-02 | 4.815E-02 | TP53; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.430E-02 | 3.629E-02 | NFKB1; MTOR |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.392E-02 | 3.624E-02 | CASP3; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.469E-02 | 3.660E-02 | CA2; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.630E-02 | 3.785E-02 | CASP3; NFKB1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.620E-03 | 7.926E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.293E-02 | 3.544E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A; DRD1; DRD2; DRD2; HTR1A |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| NA: NA | Schizoaffective disorder | NA | PDE10A; HTR1A |
| NA: NA | Vomiting | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| NA: NA | Episode | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PDE5A; HTR2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR1A |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR; CA9 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1; DRD2; DRD2; DRD2; DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PDE5A |
| NA: NA | Itching | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | OPRM1; OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; MTOR; CA9; NFKB1; CASP3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; HTR1A |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2; CYP2D6 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MTOR; CA9; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | OPRM1; HTR1A; HTR2A; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; CREBBP |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PDE5A; OPRM1; DRD2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; DRD2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; DRD2; HTR1A; HTR2A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | PDE5A; DRD2 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1; DRD1; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1; OPRM1 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE5A; DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1; OPRD1; DRD2; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | PDE10A; PDE10A; HTR7; DRD1; DRD2; DRD2; DRD2; DRD2; HTR1A; HTR1A; HTR2A; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1; OPRD1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | PDE2A; HTR1A; HTR2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| NA: NA | Addiction | NA | HTR2A |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; HTR1A |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; DRD2; HTR2A |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A; HTR1A |
| NA: NA | Social phobia | NA | HTR1A |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; HTR1A |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR; OPRM1; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| NA: NA | False perceptions | NA | DRD2 |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; OPRM1; DRD2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRK1; OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR1A; HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| NA: NA | Hyperaemia | NA | DRD2 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; OPRM1; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR7; OPRM1; DRD2; HTR1A; HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | PDE10A; DRD2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1; PDE2A; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; HTR1A; HTR1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRK1; OPRD1; MTOR; OPRM1; OPRM1; DRD1; DRD2; HTR1A; PKM |